| Literature DB >> 34348632 |
Issa Pour-Ghaz1, Mark Heckle1, Ikechukwu Ifedili1, Sharif Kayali2, Christopher Nance2, Rajesh Kabra1,3, Sunil K Jha1,3, John L Jefferies1,3, Yehoshua C Levine1,3.
Abstract
Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for patients at risk for sudden cardiac death due to ventricular tachyarrhythmia. The most commonly used risk stratification algorithms use Left Ventricular Ejection Fraction (LVEF) to determine which patients qualify for ICD therapy, even though LVEF is a better marker of total mortality than ventricular tachyarrhythmias mortality. This review evaluates imaging tools and novel biomarkers proposed for better risk stratifying arrhythmic substrate, thereby identifying optimal ICD therapy candidates. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Sudden cardiac death; biomarkers; cardiac MRI; implantable cardioverter defibrillator; left ventricular ejection fraction; risk stratification
Mesh:
Year: 2022 PMID: 34348632 PMCID: PMC9413734 DOI: 10.2174/1573403X17666210804125939
Source DB: PubMed Journal: Curr Cardiol Rev ISSN: 1573-403X